Science and Technology
publicado em 25/05/2013 às 10h00:00
   Dê o seu voto:

Strategy can create effective vaccine for the prevention and treatment of AIDS

Approach increases the number of viral peptides that T cells recognize improving response of immune cells to the virus

 
font size
A-
A+

Researchers at OHSU' s Vaccine and Gene Therapy Institute believe they have discovered a promising delivery method to help make an HIV vaccine effective prior to, and perhaps after, infection

A new discovery at Oregon Health & Science University highlights an ingenious method to ensure the body effectively reacts when infected with the highly evasive HIV virus that causes AIDS. The same team of researchers has been utilizing this unique approach to develop its own HIV vaccine candidate, which has so far shown promising results in animal studies. This latest research finding will be published in the May 24, 2013, edition of the journal Science.

" A major challenge in developing an effective HIV vaccine is figuring out how to target this evasive virus," said Dr. Louis Picker, associate director of the OHSU Vaccine and Gene Therapy Institute, where the work was conducted.

CD8+ " cytotoxic" T cells are an important component of the immune system and are particularly important for pathogens, like HIV, that easily evade antibodies. They serve as sentries within the body that detect and destroy virus-infected cells, accomplishing this function by recognizing short viral peptides on the surface of infected cells. T-cells are designed to be quite frugal in the number of different viral peptides they recognize, typically responding to just a handful of such peptides. This is a problem for control of HIV, which is able to change its peptides and thus escape T cells responses that do not target the relatively few functionally critical peptides that can' t change without debilitating the virus. In the vast majority of HIV infections, the few viral peptides recognized by T cells are not the vulnerable ones, and the virus escapes.

Therefore, the strategy that Dr. Picker and his colleagues adopted was to try to develop a vaccine to increase the number of viral peptides that T cells would recognize, reasoning that increasing this " recognition breadth" would allow T cells to more effectively respond to HIV.

The researchers found that cytomegalovirus or CMV, a common virus already carried by a large percentage of the population, may hold the key. Their studies in the non-human primate model of HIV, called SIV, found that a modified version of CMV engineered to express SIV proteins generates SIV-specific T cells that recognize three-fold as many SIV peptides as T cells generated by conventional vaccines and SIV itself. Moreover, these responses were entirely different from conventional responses, such that even viruses that had previously escaped natural responses would still be vulnerable. In effect, the hunters of the body were provided with a much better targeting system to help them find and destroy an elusive enemy.

Picker and his colleagues believe an HIV vaccine equipped with a modified CMV vector might be able to both prevent infection (prophylactic vaccine) and effectively battle the virus even if applied post-infection in individuals with infections suppressed by anti-retroviral therapy. Moving forward, the research team hopes to utilize this new information to create customized CMV vectors with a broad ability to identify several components of HIV and then incorporate this component into an effective vaccine.

" We hope we can begin clinical trials in human patients within a few years," explained Dr. Picker. " This new information gives us a much clearer roadmap for effectively targeting the disease which to this point has found ways to evade the human immune system."

National Institutes of Health (P01 AI094417, R01 AI060392, R01 AI059457, P51 OD 011092 and contract #HHSN261200800001E), the Bill & Melinda Gates Foundation and the International AIDS Vaccine Initiative funded this research.

OHSU and paper authors Drs. Picker, Hansen, Fru?h and Nelson have a significant financial interest in TomegaVax, Inc., a company that may have a commercial interest in the results of this research and technology. The potential individual and institutional conflicts of interest have been reviewed and managed by OHSU.

Source: OREGON STATE UNIVERSITY
   Palavras-chave:   HIV vaccine    HIV    AIDS    T cells    Viral peptides    Oregon Health & Science University    Louis Picker   
  • Share this pageShare this page
  • Share this pageCorrect
  • ShareShare
  • AlertAlert
Reduced link: 
  • You are recommending this story: Strategy can create effective vaccine for the prevention and treatment of AIDS
  • Fill in the following form to send your recommendation to your friend:

  • You are suggesting a correction for this story: Strategy can create effective vaccine for the prevention and treatment of AIDS


Receba notícias do iSaúde no seu e-mail de acordo com os assuntos de seu interesse.
Seu nome:
Seu email:
Desejo receber um alerta com estes assuntos:
HIV vaccine    HIV    AIDS    T cells    viral peptides    Oregon Health & Science University    Louis Picker   
Comments:
Comment
Leave your comment
Close
(Required fields are marked with an *)

(Your email address will never be published or shared.)

Enter the letters and numbers below and click in the button "send"

  • Twitter iSaúde
advertising
Informe Saúde printed version

Recommend the portal
Close [X]
  • You are recommending this story: http://www.isaude.net
  • Fill in the following form to send your recommendation to your friend:

RSS news from the portal  iSaúde.net
Get the newsletter of the portal  iSaúde.net
Recommend the portal iSaúde.net
News from  iSaúde.net in your blog or website.
Get news on the subject of your interest.
© 2000-2011 www.isaude.net Todos os direitos reservados.